SCHEMBL322293

SCHEMBL322293

CCCn1c(=O)n(Cc2cccs2)c(=O)c2cc(C(=O)c3nc(-c4cccc(C(=O)O)c4)c4ccccn34)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
HPGD P15428 2/20 0.40
RORC P51449 10/20 0.39
HDAC1 Q13547 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
CFTR P13569 1/20 0.38
NPC1 O15118 1/20 0.36
PTGER4 P35408 1/20 0.36
PPARG P37231 1/20 0.36
TSHR P16473 2/20 0.35
MAPK1 P28482 2/20 0.35
LMNA P02545 2/20 0.35
GBA1 P04062 1/20 0.35
MAPT P10636 1/20 0.35
UBE2N P61088 1/20 0.35
RECQL P46063 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CNR2 P34972 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14916117 0.90 HPGD (0.40) ALDH1A1HPGDRORCNPC1PTGER4
SCHEMBL322637 0.86 HDAC1 (0.44) ALDH1A1HPGDRORCHDAC1HDAC11
SCHEMBL322447 0.85 RORC (0.44) ALDH1A1HPGDRORCNPC1PPARG
SCHEMBL15093887 0.84 ALDH1A1 (0.41) ALDH1A1HPGDRORCNPC1PPARG
SCHEMBL14917381 0.82 RORC (0.41) RORCPPARG
SCHEMBL322510 0.81 ALDH1A1 (0.39) ALDH1A1HPGDRORCHDAC1HDAC11
SCHEMBL321910 0.81 RORC (0.44) ALDH1A1HPGDRORCPPARGTSHR
SCHEMBL321765 0.79 RORC (0.43) ALDH1A1HPGDRORCPPARGRECQL
SCHEMBL15093752 0.79 HDAC1 (0.44) ALDH1A1RORCHDAC1HDAC11HDAC8
SCHEMBL322594 0.78 MMP13 (0.46) RORCHDAC1HDAC11HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452164-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2016-09-27 US disclosed
EP-2590976-B1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-09-16 EP disclosed
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-28 US disclosed
US-8759344-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2014-06-24 US disclosed
EP-2590976-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 EP disclosed
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
WO-2012004732-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH ALDH1A1 2306/4885HPGD 630/4885RORC 1361/4885
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH ALDH1A1 2306/4885HPGD 630/4885RORC 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.